Overview

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Status:
TERMINATED

Trial end date:
2023-11-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.

Phase:

PHASE2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Alzheimer's Association
Hoffmann-La Roche
National Institute on Aging (NIA)

Treatments:

gantenerumab